These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26530358)

  • 1. Use of Biomarkers in Screening for Cancer.
    Duffy MJ
    Adv Exp Med Biol; 2015; 867():27-39. PubMed ID: 26530358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Biomarkers in Screening for Cancer.
    Duffy MJ
    EJIFCC; 2010 Mar; 21(1):1-12. PubMed ID: 27683350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality.
    Kamal R; Hamed S; Mansour S; Mounir Y; Abdel Sallam S
    Br J Radiol; 2018 Oct; 91(1090):20170571. PubMed ID: 30102555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor markers in clinical practice: a review focusing on common solid cancers.
    Duffy MJ
    Med Princ Pract; 2013; 22(1):4-11. PubMed ID: 22584792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
    Duffy MJ; van Rossum LG; van Turenhout ST; Malminiemi O; Sturgeon C; Lamerz R; Nicolini A; Haglund C; Holubec L; Fraser CG; Halloran SP
    Int J Cancer; 2011 Jan; 128(1):3-11. PubMed ID: 20824704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for the early detection of cancer: an inflammatory concept.
    Roy HK; Khandekar JD
    Arch Intern Med; 2007 Sep; 167(17):1822-4. PubMed ID: 17893302
    [No Abstract]   [Full Text] [Related]  

  • 9. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples.
    Guittet L; Bouvier V; Mariotte N; Vallee JP; Levillain R; Tichet J; Launoy G
    Int J Cancer; 2009 Sep; 125(5):1127-33. PubMed ID: 19431212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of common seric tumor markers in patients with solid cancers.
    Gara S; Boussen H; Ghanem A; Guemira F
    Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA in screening for prostate cancer: more good than harm or more harm than good?
    Duffy MJ
    Adv Clin Chem; 2014; 66():1-23. PubMed ID: 25344984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.
    Birnbaum JK; Feng Z; Gulati R; Fan J; Lotan Y; Wei JT; Etzioni R
    Cancer Epidemiol Biomarkers Prev; 2015 Apr; 24(4):677-82. PubMed ID: 25613117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current results on PSA-based prostate cancer detection].
    Graefen M; Schlomm T; Steuber T; Sauter G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of colorectal cancer with faecal occult blood test screening.
    Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
    Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for colorectal cancer in Italy, 2009 survey.
    Zorzi M; Baracco S; Fedato C; Grazzini G; Sassoli De' Bianchi P; Senore C; Visioli CB; Cogo C
    Epidemiol Prev; 2011; 35(5-6 Suppl 5):55-77. PubMed ID: 22166350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy?
    van Dam L; Korfage IJ; Kuipers EJ; Hol L; van Roon AH; Reijerink JC; van Ballegooijen M; van Leerdam ME
    Eur J Cancer; 2013 Jul; 49(10):2321-30. PubMed ID: 23571149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
    Musil D; Tillich J
    Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up.
    Scholefield JH; Moss SM; Mangham CM; Whynes DK; Hardcastle JD
    Gut; 2012 Jul; 61(7):1036-40. PubMed ID: 22052062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Clinician's Guide to Fecal Occult Blood Testing for Colorectal Cancer.
    Bechtold ML; Ashraf I; Nguyen DL
    South Med J; 2016 Apr; 109(4):248-55. PubMed ID: 27043809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.